Could cause temporary or reversible harm; serious harm is unlikely.
Superpotent drug: Out of specification test result for assay during stability testing.
| Brand name | AMOXICILLIN |
| Generic name | AMOXICILLIN |
| Active ingredient(s) | AMOXICILLIN |
| Distributed by / for | Teva North America |
| NDC | 0093-4161-76 |
| Full product label | Amoxicillin for Oral Suspension USP, 400 mg/ 5 mL, 50 mL bottle, Rx only, Manufactured In Canada by: Teva Canada Limited, Toronto, Canada, NDC 0093-4161-76 |
| Recalling firm | Teva North America |
| Distribution | Nationwide |
| Quantity | 53,328 bottles |
| Recall initiated | 2016-06-24 |
| Report date | 2016-08-31 |
| Recall completed | 2017-02-07 |
| Recall number | D-1470-2016 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Horsham PA United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗